Wikiversity

Progress and Prospects in Parkinson's Research/Therapy/Neuroprotection/Probuool

< Progress and Prospects in Parkinson's Research | Therapy | Neuroprotection
(Redirected from PD Neuroprotection/Probuool)

Probucol is a lipid-lowering phenolic compound with anti-inflammatory and antioxidant properties that has been recently reported as protective in neurotoxicity and neurodegeneration models.

Research

edit

2013

Ribeiro et al[1]tested the efficacy of the drug. Swiss mice were treated with probucol during 21 days (11.8 mg/kg; oral route). Two weeks after the beginning of treatment, mice received a single intracerebroventricular (i.c.v.) infusion of 6-hydroxydopamine (6-OHDA).

On the 21st day, locomotor performance, striatal oxidative stress-related parameters, and striatal tyrosine hydroxylase and synaptophysin levels, were measured as outcomes of toxicity. 6-OHDA-infused mice showed hyperlocomotion and a significant decrease in striatal tyrosine hydroxylase (TH) and synaptophysin levels. In addition, 6-OHDA-infused mice showed reduced superoxide dismutase activity and increased lipid peroxidation and catalase activity in the striatum.

Further Reading

edit

Today

Use the following links to query the PubMed, PubMed Central and Google Scholar databases using the Search terms:- Parkinson's_Disease Probucol.

This will list the latest papers on this topic. You are invited to update this page to reflect such recent results, pointing out their significance.

Pubmed (abstracts)

Pubmed_Central (Full_Text)

Google_Scholar

References

edit

<references>

  1. ↑ Ribeiro, R.P.; Moreira, E.L; Santos, D.B,.; Colle, D.; Dos Santos, A.A.; Peres, K.C.; Figueiredo, C.P. and Farina, M. (2013)@ Abstract Neurochem. Res. 2013 Jan 19. Probucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson's Disease. http://www.ncbi.nlm.nih.gov/pubmed/23334712
Retrieved from "https://en.wikiversity.org/w/index.php?title=Progress_and_Prospects_in_Parkinson%27s_Research/Therapy/Neuroprotection/Probuool&oldid=2570738"